NCI-话题@MedSci

#NCI#

172篇内容 | 3553人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1933760, encodeId=b2841933e60a7, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, objectTitle=PD-L1单抗Bavencio：正在欧洲接受审查以治疗转移性尿路上皮癌, objectType=article, longId=196293, objectId=15011962937c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15011962937c, replyNumber=0, likeNumber=50, createdTime=2021-04-29, rootId=0, userName=lanyan20020086, userId=0ee7414, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15011962937c, moduleTitle=PD-L1单抗Bavencio：正在欧洲接受审查以治疗转移性尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15011962937c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1933763, encodeId=d47b1933e63c8, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, objectTitle=PD-L1单抗Bavencio+阿昔替尼：获英国NICE推荐作为晚期肾癌的一线疗法, objectType=article, longId=198551, objectId=2cb719855145, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cb719855145, replyNumber=0, likeNumber=68, createdTime=2021-02-02, rootId=0, userName=lanyan20020086, userId=0ee7414, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cb719855145, moduleTitle=PD-L1单抗Bavencio+阿昔替尼：获英国NICE推荐作为晚期肾癌的一线疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2cb719855145)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1933762, encodeId=8bb31933e6294, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, objectTitle=PD-L1单抗Bavencio，获得FDA批准用于晚期或转移性尿路上皮癌患者的维持治疗, objectType=article, longId=196892, objectId=c2de19689221, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2de19689221, replyNumber=0, likeNumber=58, createdTime=2021-04-02, rootId=0, userName=lanyan20020086, userId=0ee7414, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2de19689221, moduleTitle=PD-L1单抗Bavencio，获得FDA批准用于晚期或转移性尿路上皮癌患者的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2de19689221)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1933759, encodeId=99941933e59d2, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, objectTitle=JNCI: 如何提高胰腺癌预后？改善筛查，早期诊断！, objectType=article, longId=190613, objectId=50ac19061356, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50ac19061356, replyNumber=0, likeNumber=72, createdTime=2021-01-21, rootId=0, userName=lanyan20020086, userId=0ee7414, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50ac19061356, moduleTitle=JNCI: 如何提高胰腺癌预后？改善筛查，早期诊断！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50ac19061356)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1933758, encodeId=a53a1933e5863, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, objectTitle=Blood：Brincidofovir预后异基因HCT后6B型人疱疹病毒感染的效果, objectType=article, longId=188538, objectId=3765188538a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3765188538a7, replyNumber=0, likeNumber=62, createdTime=2020-06-01, rootId=0, userName=lanyan20020086, userId=0ee7414, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3765188538a7, moduleTitle=Blood：Brincidofovir预后异基因HCT后6B型人疱疹病毒感染的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3765188538a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1933755, encodeId=f9ce1933e55a8, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, objectTitle=Blood：2期临床试验：Concizumab可有效预防各型血友病患者出血, objectType=article, longId=178314, objectId=3d3e1e8314ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d3e1e8314ea, replyNumber=0, likeNumber=85, createdTime=2020-01-26, rootId=0, userName=lanyan20020086, userId=0ee7414, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d3e1e8314ea, moduleTitle=Blood：2期临床试验：Concizumab可有效预防各型血友病患者出血, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d3e1e8314ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1933757, encodeId=f0341933e57d1, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, objectTitle=默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点, objectType=article, longId=185843, objectId=5f5518584350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f5518584350, replyNumber=0, likeNumber=71, createdTime=2020-03-09, rootId=0, userName=lanyan20020086, userId=0ee7414, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f5518584350, moduleTitle=默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f5518584350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1933756, encodeId=93961933e5627, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, objectTitle=J Endod：Gow-Gates, Vazirani-Akinosi和Mental Incisive神经阻滞对有症状不可逆牙髓炎的麻醉效果比较, objectType=article, longId=180412, objectId=e63e18041230, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e63e18041230, replyNumber=0, likeNumber=58, createdTime=2020-07-06, rootId=0, userName=lanyan20020086, userId=0ee7414, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e63e18041230, moduleTitle=J Endod：Gow-Gates, Vazirani-Akinosi和Mental Incisive神经阻滞对有症状不可逆牙髓炎的麻醉效果比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e63e18041230)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1933752, encodeId=f77a1933e5214, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, objectTitle=2019年国际血栓和止血学会：II期临床试验抗组织因子抑制剂单抗Concizumab对A/B型血友病患者安全有效, objectType=article, longId=175613, objectId=674d1e56136b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=674d1e56136b, replyNumber=0, likeNumber=77, createdTime=2020-02-13, rootId=0, userName=lanyan20020086, userId=0ee7414, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=674d1e56136b, moduleTitle=2019年国际血栓和止血学会：II期临床试验抗组织因子抑制剂单抗Concizumab对A/B型血友病患者安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=674d1e56136b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1933753, encodeId=fe4d1933e53f0, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, objectTitle=英国MHRA给予Bavencio和Inlyta治疗晚期肾细胞癌，早期药品计划（EAMS）的指定, objectType=article, longId=176035, objectId=15c61e603593, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15c61e603593, replyNumber=0, likeNumber=61, createdTime=2020-01-20, rootId=0, userName=lanyan20020086, userId=0ee7414, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15c61e603593, moduleTitle=英国MHRA给予Bavencio和Inlyta治疗晚期肾细胞癌，早期药品计划（EAMS）的指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15c61e603593)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1933748, encodeId=574c1933e48c8, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, objectTitle=JNCI：20年研究证明：维生素E降低or提高癌症的风险和基因有关, objectType=article, longId=158051, objectId=fe8d1580519c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe8d1580519c, replyNumber=0, likeNumber=59, createdTime=2019-12-23, rootId=0, userName=lanyan20020086, userId=0ee7414, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe8d1580519c, moduleTitle=JNCI：20年研究证明：维生素E降低or提高癌症的风险和基因有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe8d1580519c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1933754, encodeId=7d951933e5484, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, objectTitle=JCO：吉西他滨 - 艾日布林组合治疗转移性尿路上皮癌患者：最终报告（NCI-9653）, objectType=article, longId=177452, objectId=7d2e1e7452d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d2e1e7452d0, replyNumber=0, likeNumber=78, createdTime=2019-12-20, rootId=0, userName=lanyan20020086, userId=0ee7414, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d2e1e7452d0, moduleTitle=JCO：吉西他滨 - 艾日布林组合治疗转移性尿路上皮癌患者：最终报告（NCI-9653）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d2e1e7452d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1933750, encodeId=46961933e50f7, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, objectTitle=2019年美国皮肤病学会会议：Principia Biopharma将宣布疱疮寻常型试验的全新数据, objectType=article, longId=161013, objectId=3a4b1610135a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a4b1610135a, replyNumber=0, likeNumber=70, createdTime=2019-04-05, rootId=0, userName=lanyan20020086, userId=0ee7414, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a4b1610135a, moduleTitle=2019年美国皮肤病学会会议：Principia Biopharma将宣布疱疮寻常型试验的全新数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a4b1610135a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1933749, encodeId=faec1933e49c4, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, objectTitle=NEJM: BAVENCIO（avelumab）联合INLYTA（阿西替尼）在晚期肾细胞癌中的关键性III期数据, objectType=article, longId=160425, objectId=2800160425be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2800160425be, replyNumber=0, likeNumber=79, createdTime=2020-01-15, rootId=0, userName=lanyan20020086, userId=0ee7414, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2800160425be, moduleTitle=NEJM: BAVENCIO（avelumab）联合INLYTA（阿西替尼）在晚期肾细胞癌中的关键性III期数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2800160425be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1933751, encodeId=832a1933e517a, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, objectTitle=欧洲药品管理局验证了默克PD-L1单抗Bavencio在晚期肾细胞癌中的疗效, objectType=article, longId=161940, objectId=45871619401a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45871619401a, replyNumber=0, likeNumber=57, createdTime=2019-10-27, rootId=0, userName=lanyan20020086, userId=0ee7414, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45871619401a, moduleTitle=欧洲药品管理局验证了默克PD-L1单抗Bavencio在晚期肾细胞癌中的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45871619401a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1933744, encodeId=6a461933e4411, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, objectTitle=JNCI；建议对三阴性乳腺癌进行多基因遗传肿瘤panel检测, objectType=article, longId=146519, objectId=6fa5146519a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fa5146519a0, replyNumber=0, likeNumber=90, createdTime=2018-09-16, rootId=0, userName=lanyan20020086, userId=0ee7414, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fa5146519a0, moduleTitle=JNCI；建议对三阴性乳腺癌进行多基因遗传肿瘤panel检测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fa5146519a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1933746, encodeId=ca951933e46ca, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, objectTitle=Principia 制药宣布PRN1008获得FDA孤儿药认定用于治疗免疫性血小板减少性紫癜, objectType=article, longId=151535, objectId=817b1515353f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=817b1515353f, replyNumber=0, likeNumber=64, createdTime=2019-03-27, rootId=0, userName=lanyan20020086, userId=0ee7414, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=817b1515353f, moduleTitle=Principia 制药宣布PRN1008获得FDA孤儿药认定用于治疗免疫性血小板减少性紫癜, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=817b1515353f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1933747, encodeId=8b2b1933e47df, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, objectTitle=ArQule在第30届EORTC / AACR / NCI研讨会上介绍了ARQ 751的全新数据, objectType=article, longId=153907, objectId=c34115390e7b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c34115390e7b, replyNumber=0, likeNumber=80, createdTime=2019-08-04, rootId=0, userName=lanyan20020086, userId=0ee7414, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c34115390e7b, moduleTitle=ArQule在第30届EORTC / AACR / NCI研讨会上介绍了ARQ 751的全新数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c34115390e7b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1933743, encodeId=378c1933e43bb, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, objectTitle=Blood：NCI标准风险的费城样ALL患者的基因组和预后分析, objectType=article, longId=144396, objectId=183314439657, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=183314439657, replyNumber=0, likeNumber=62, createdTime=2019-01-26, rootId=0, userName=lanyan20020086, userId=0ee7414, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=183314439657, moduleTitle=Blood：NCI标准风险的费城样ALL患者的基因组和预后分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=183314439657)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1933731, encodeId=4a021933e3102, content=<a href='/topic/show?id=71a81258504' target=_blank style='color:#2F92EE;'>#NCI#</a>, objectTitle=JNCI: 冷冻疗法可预防化疗引起的神经病变, objectType=article, longId=117048, objectId=3fb011e04890, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fb011e04890, replyNumber=0, likeNumber=72, createdTime=2018-07-20, rootId=0, userName=lanyan20020086, userId=0ee7414, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fb011e04890, moduleTitle=JNCI: 冷冻疗法可预防化疗引起的神经病变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fb011e04890)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

NCI

2020-05-29

lanyan20020086 (审核中...)

前往app查看评论内容

#NCI#

PD-L1单抗Bavencio：正在欧洲接受审查以治疗转移性尿路上皮癌

2021-04-29

lanyan20020086 (审核中...)

前往app查看评论内容

#NCI#

PD-L1单抗Bavencio+阿昔替尼：获英国NICE推荐作为晚期肾癌的一线疗法

2021-02-02

lanyan20020086 (审核中...)

前往app查看评论内容

#NCI#

PD-L1单抗Bavencio，获得FDA批准用于晚期或转移性尿路上皮癌患者的维持治疗

2021-04-02

lanyan20020086 (审核中...)

前往app查看评论内容

#NCI#

JNCI: 如何提高胰腺癌预后？改善筛查，早期诊断！

2021-01-21

lanyan20020086 (审核中...)

前往app查看评论内容

#NCI#

Blood：Brincidofovir预后异基因HCT后6B型人疱疹病毒感染的效果

2020-06-01

lanyan20020086 (审核中...)

前往app查看评论内容

#NCI#

Blood：2期临床试验：Concizumab可有效预防各型血友病患者出血

2020-01-26

lanyan20020086 (审核中...)

前往app查看评论内容

#NCI#

默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点

2020-03-09

lanyan20020086 (审核中...)

前往app查看评论内容

#NCI#

J Endod：Gow-Gates, Vazirani-Akinosi和Mental Incisive神经阻滞对有症状不可逆牙髓炎的麻醉效果比较

2020-07-06

lanyan20020086 (审核中...)

前往app查看评论内容

#NCI#

2019年国际血栓和止血学会：II期临床试验抗组织因子抑制剂单抗Concizumab对A/B型血友病患者安全有效

2020-02-13

lanyan20020086 (审核中...)

前往app查看评论内容

#NCI#

英国MHRA给予Bavencio和Inlyta治疗晚期肾细胞癌，早期药品计划（EAMS）的指定

2020-01-20

lanyan20020086 (审核中...)

前往app查看评论内容

#NCI#

JNCI：20年研究证明：维生素E降低or提高癌症的风险和基因有关

2019-12-23

lanyan20020086 (审核中...)

前往app查看评论内容

#NCI#

JCO：吉西他滨 - 艾日布林组合治疗转移性尿路上皮癌患者：最终报告（NCI-9653）

2019-12-20

lanyan20020086 (审核中...)

前往app查看评论内容

#NCI#

2019年美国皮肤病学会会议：Principia Biopharma将宣布疱疮寻常型试验的全新数据

2019-04-05

lanyan20020086 (审核中...)

前往app查看评论内容

#NCI#

NEJM: BAVENCIO（avelumab）联合INLYTA（阿西替尼）在晚期肾细胞癌中的关键性III期数据

2020-01-15

lanyan20020086 (审核中...)

前往app查看评论内容

#NCI#

欧洲药品管理局验证了默克PD-L1单抗Bavencio在晚期肾细胞癌中的疗效

2019-10-27

lanyan20020086 (审核中...)

前往app查看评论内容

#NCI#

JNCI；建议对三阴性乳腺癌进行多基因遗传肿瘤panel检测

2018-09-16

lanyan20020086 (审核中...)

前往app查看评论内容

#NCI#

Principia 制药宣布PRN1008获得FDA孤儿药认定用于治疗免疫性血小板减少性紫癜

2019-03-27

lanyan20020086 (审核中...)

前往app查看评论内容

#NCI#

ArQule在第30届EORTC / AACR / NCI研讨会上介绍了ARQ 751的全新数据

2019-08-04

lanyan20020086 (审核中...)

前往app查看评论内容

#NCI#

Blood：NCI标准风险的费城样ALL患者的基因组和预后分析

2019-01-26

lanyan20020086 (审核中...)

前往app查看评论内容

#NCI#

JNCI: 冷冻疗法可预防化疗引起的神经病变

2018-07-20

科室
- - 订阅+
  - 更多科室
工具
服务